Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States-Reference-Cited by-同舟云学术

Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States

Published:2023-03-09 Issue:8 Volume:23 Page:841-849
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Xue Xiangzhong¹^ORCID,Truong Bang¹^ORCID,Qian Jingjing¹^ORCID

Affiliation:

1. Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, Auburn, AL, USA

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2189007

Reference47 articles.

1. Cancer statistics for the year 2020: An overview

2. Centers for Disease Control and Prevention. Leading causes of death. 2022 [Cited 2022 Sep 1] Available from: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm

3. American Cancer Society. Cancer Facts & Figures. 2022 [Cited 2022 Aug 31] Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html

4. Biological impediments to monoclonal antibody–based cancer immunotherapy

5. Monoclonal Antibodies in Cancer Therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Biosimilar in Lung Cancer;Biosimilars for Cancer Treatment;2024

3. Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective;BioDrugs;2023-08-05